查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1528988

地中海貧血治療市場- 按治療類型（輸血、鐵螯合療法、葉酸補充劑）、按疾病類型（α 地中海貧血、BETA 地中海貧血）、最終用途（醫院、超級專科診所）和預測，2024 年- 2032年

Thalassemia Treatment Market - By Treatment Type (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements), By Disease Type (Alpha Thalassemia, Beta Thalassemia), By End-use (Hospitals, Super Specialty Clinics) & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 95 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於地中海貧血盛行率上升，預計 2024 年至 2032 年地中海貧血治療市場複合年成長率為 7.4%。根據《柳葉刀》報告，全球地中海貧血盛行率約為每 10 萬人中 18.28 例。地中海貧血的發生率較高，尤其是在地中海貧血、中東和亞洲部分地區等帶菌率較高的地區，促使醫療保健系統更加重視控制這種疾病。由於需要先進的治療方案和全面的護理策略，因此需要在研究、開發和採用創新療法方面進行投資，以更好地滿足全球地中海貧血患者的需求。

此外，人們也非常關注藥物配方的創新和基因療法的突破。這些進步不僅提高了治療的有效性，而且旨在提供長期解決方案，有可能改變地中海貧血的治療。尖端療法和個人化醫療的結合將刺激市場成長，改善患者的治療效果並解決地中海貧血護理中未滿足的需求。

地中海貧血治療產業根據治療類型、疾病類型、最終用途和地區進行分類。

到 2032 年，葉酸補充劑領域將佔據主導地位，因為葉酸（一種 B 群維生素）在新細胞（包括紅血球）的產生和維持中發揮著至關重要的作用。對於地中海貧血患者來說，葉酸補充劑對於支持紅血球生成和減輕貧血至關重要。它有助於控制病情並改善患者的整體健康。隨著人們越來越認知到葉酸在地中海貧血治療中的益處，對這些補充劑的需求不斷成長。

超級專科診所部分將在 2032 年之前獲得關注，因為它們專注於為地中海貧血患者提供專業護理和先進的治療選擇。他們提供全面的治療計劃，包括輸血、螯合療法和骨髓移植，以滿足地中海貧血患者的特定需求。由於疾病的複雜性和對專家管理的需求，人們對專業護理的偏好日益成長，導致越來越多的患者在超級專業診所尋求治療。

在先進的醫療基礎設施以及針對遺傳性疾病的強大支持系統的推動下，歐洲地中海貧血治療市場規模將在 2032 年快速成長。歐洲國家也在研發投資，以增強治療選擇並改善病患的治療效果。此外，歐洲各地都有成熟的醫療機構和專科診所。歐盟透過資金和政策支持解決包括地中海貧血在內的罕見遺傳疾病的舉措進一步推動了市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 地中海貧血盛行率增加
      • 技術進步
      • 對地中海貧血治療的認知提高
      • 研發投資激增
    • 產業陷阱與挑戰
      • 嚴格的監管場景
      • 治療費用高
  • 成長潛力分析
  • 報銷場景
  • 監管環境
  • 技術景觀
  • 新興療法
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • 輸血
  • 鐵螯合療法
  • 葉酸補充劑
  • 其他治療類型

第 6 章：市場估計與預測：按疾病類型，2021 - 2032

  • 主要趨勢
  • α地中海貧血
  • BETA地中海型貧血

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 超專科診所
  • 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Bluebird Bio
  • Bristol-Myers Squibb Company
  • CHIESI Farmaceutici S.p.A.
  • Kiadis Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SG Phrma Pvt. Lmt.
簡介目錄
Product Code: 9438

The Thalassemia Treatment Market is estimated to register a 7.4% CAGR during 2024-2032, driven by the rising prevalence of thalassemia. According to the Lancet report, the global prevalence of thalassemia is approximately 18.28 cases per 100,000 individuals. The higher incidence of thalassemia, particularly in regions with higher carrier rates, such as parts of the Mediterranean, Middle East, and Asia, is pushing healthcare systems to enhance their focus on managing the disorder. With the need for advanced therapeutic options and comprehensive care strategies, there are investments in research, development, and the adoption of innovative treatments to better address the needs of thalassemia patients worldwide.

Furthermore, there is a strong focus on innovating drug formulation and breakthroughs in gene therapy. These advancements not only enhance the effectiveness of treatments but also aim to provide long-term solutions, potentially transforming the management of thalassemia. The incorporation of cutting-edge therapies and personalized medicine will stimulate market growth, improving patient outcomes and addressing unmet needs in thalassemia care.

The thalassemia treatment industry is classified based on treatment type, disease type, end-use, and region.

The folic acid supplements segment will gain prominence through 2032, as folic acid, a B vitamin, plays a crucial role in the production and maintenance of new cells, including red blood cells. For patients with thalassemia, folic acid supplements are essential to support red blood cell production and mitigate anemia. It helps in managing the condition and improving overall patient health. With increasing recognition of the benefits of folic acid in thalassemia management, there is a growing demand for these supplements.

The super specialty clinics segment will gain traction through 2032, owing to their focus on providing specialized care and advanced treatment options for thalassemia patients. They offer comprehensive treatment plans, including blood transfusions, chelation therapy, and bone marrow transplants, tailored to the specific needs of thalassemia patients. The growing preference for specialized care, driven by the complexity of the disorder and the need for expert management, is leading to an increased number of patients seeking treatment at super specialty clinics.

Europe thalassemia treatment market size will grow rapidly through 2032, driven by an advanced healthcare infrastructure, coupled with robust support systems for genetic disorders. European countries are also investing in R&D to enhance treatment options and improve patient outcomes. Additionally, there is presence of established healthcare institutions and specialized clinics across Europe. The European Union's initiatives to address rare and genetic diseases, including thalassemia, through funding and policy support, further drive market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of thalassemia
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rise in awareness regarding thalassemia treatment
      • 3.2.1.4 Surge in R&D investments
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory scenario
      • 3.2.2.2 High cost of treatment
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
  • 3.7 New emerging therapies
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Blood transfusions
  • 5.3 Iron chelation therapy
  • 5.4 Folic acid supplements
  • 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Alpha thalassemia
  • 6.3 Beta thalassemia

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Super specialty clinics
  • 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Bluebird Bio
  • 9.2 Bristol-Myers Squibb Company
  • 9.3 CHIESI Farmaceutici S.p.A.
  • 9.4 Kiadis Pharma
  • 9.5 Merck & Co., Inc.
  • 9.6 Novartis AG
  • 9.7 Pfizer, Inc.
  • 9.8 SG Phrma Pvt. Lmt.